Mode
Text Size
Log in / Sign up

Venous thrombosis

Part of Embolism and Thrombosis

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for venous thrombosis

35 trials tracked for venous thrombosis: 14 in phase 3 or 4 and 3 with published results. The most-cited published study has 774 citations.

35Trials tracked
14Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 13 Phase 2 5 Phase 1 1 Other / NA 15
  1. Phase 3 Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) Completed · 774 cited
  2. Phase 3 Evaluation of the Duration of Therapy for Thrombosis in Children Completed · 98 cited
  3. Phase 3 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Completed · 87 cited
  4. Phase 4 Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT Completed
  5. Phase 3 Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium) Completed
  6. Phase 3 The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients Completed
Show 29 more trials
  1. Phase 3 Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy. Completed
  2. Phase 3 Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Completed
  3. Phase 3 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed
  4. Phase 3 Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) Completed
  5. Phase 3 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed
  6. Phase 3 Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study Completed
  7. Phase 3 A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery Completed
  8. Phase 3 Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness Completed
  9. Phase 2 A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis Completed
  10. Phase 2 Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients Completed
  11. Phase 2 Oral Rivaroxaban in Children With Venous Thrombosis Completed
  12. Phase 2 Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer Completed
  13. Phase 2 A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery. Completed
  14. Phase 1 Switching Study From Warfarin to Rivaroxaban Completed
  15. N/A Registry of AngioJet Use in the Peripheral Vascular System Completed
  16. N/A Educating Nurses About Venous Thromboembolism (VTE) Prevention Completed
  17. N/A Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters Completed
  18. N/A Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture Completed
  19. N/A Hemorrhage Risk Prescribed Arixtra Completed
  20. N/A Tranexamic Acid and Blood Clots in Knee Surgery Completed
  21. N/A Study Of Lybrel In Relation To Venous Thromboembolism Completed
  22. N/A Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis Completed
  23. N/A A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters Completed
  24. N/A JETi Lower Extremity Venous Thrombosis Completed
  25. N/A A Preliminary Clinical Usability Study for the Recovery Force DVT II Cuff Completed
  26. N/A Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism Completed
  27. N/A Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery Completed
  28. N/A Vasculaire Compression System Increases Flow Velocity in the Femoral Vein Completed
  29. N/A Comparison of Different Intermittent Pneumatic Compression Devices for Deep Vein Thrombosis Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Venous thrombosis: what the trials found

Several anticoagulant agents have demonstrated efficacy in managing venous thromboembolism (VTE). Rivaroxaban significantly reduced the incidence of symptomatic recurrent VTE compared to other treatments 12 and showed a reduction in the composite of recurrent DVT, non-fatal PE, and all-cause mortality 12. BAY 59-7939 also demonstrated significant reductions in the composite of fatal or non-fatal symptomatic recurrent VTE 3, as well as in the composite of primary efficacy outcomes including myocardial infarction, ischemic stroke, or systemic non-CNS embolism 3.

Fondaparinux has shown consistent results in reducing VTE events and mortality [13, 14] and demonstrated a 0% rate of recurrent or new symptomatic VTE in specific cohorts 15. Edoxaban tosylate was associated with significantly lower rates of clinically relevant bleeding compared to other treatments 7, while Apixaban showed significant reductions in the composite of symptomatic recurrent VTE or all-cause death 10. Enoxaparin also demonstrated a statistically significant reduction in the incidence of adjudicated composite symptomatic, recurrent VTE or VTE-related death 9.

recent-not-corroborated":["JETi for lower extremity venous thrombosis showed an 84.5% success rate for $\geq$75% thrombus reduction with a 1.7% rate of major adverse events within 30 days 1."],

For the clinician treating this condition

  • Rivaroxaban and BAY 59-7939 are established options for reducing symptomatic recurrent VTE and associated mortality [3, 12].
  • Fondaparinux and Enoxaparin have demonstrated significant efficacy in preventing VTE and related deaths [9, 13, 14].
  • Edoxaban tosylate is associated with a lower incidence of clinically relevant bleeding compared to alternative treatments 7.

AI synthesis of 7 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.

Research across Embolism and Thrombosis

Related studies from across the Embolism and Thrombosis family.

DOACs reduce thrombosis recurrence and major bleeding compared to warfarin in morbidly obese VTE patients
Diabetes & Endocrinology Meta-analysis
DOACs reduce thrombosis recurrence and major bleeding compared to warfarin in morbidly obese VTE patients DOACs Show Lower Risk of Blood Clots in Patients with Obesity
This meta-analysis of 44,672 patients found that DOACs are associated with lower risks of thrombosis recurrence (OR 0.74) and major bleeding…
New data suggests that direct acting oral anticoagulants may be more effective than warfarin for managing blood clots in patients with morbi…
Gut microbiota and metabolites communicate bidirectionally with the host cardiovascular system via metabolic networks
Cardiology Sys. Review
Gut microbiota and metabolites communicate bidirectionally with the host cardiovascular system via metabolic networks Gut bacteria and their waste products impact heart health
This systematic review examines the role of gut microbiota and their metabolites in cardiovascular disease pathogenesis. The authors synthes…
New evidence shows how your gut bacteria communicate with your heart through a network of metabolites to influence cardiovascular disease.
Direct oral anticoagulants reduce thrombotic events and major bleeding in cirrhosis with atrial fibrillation or venous thromboembolism
Cardiology Meta-analysis
Direct oral anticoagulants reduce thrombotic events and major bleeding in cirrhosis with atrial fibrillation or venous thromboembolism Direct oral anticoagulants show promise for patients with liver cirrhosis
A meta-analysis of predominantly observational studies compared direct oral anticoagulants with traditional anticoagulants in patients with …
New analysis suggests direct oral anticoagulants may reduce blood clots and major bleeding risks for patients with liver cirrhosis and heart…
D-dimer shows moderate diagnostic potential for ruling out deep vein thrombosis after total joint arthroplasty
Emergency Medicine Meta-analysis
D-dimer shows moderate diagnostic potential for ruling out deep vein thrombosis after total joint arthroplasty D-dimer test helps rule out dangerous blood clots after joint replacement
This meta-analysis of 7,123 patients evaluated the diagnostic performance of D-dimer for screening deep vein thrombosis following total join…
A new analysis of over 7,000 patients finds D-dimer blood test is moderately useful for ruling out deep vein thrombosis after hip or knee re…
Ankle pump exercises plus anticoagulants reduce postoperative DVT risk
Neurology Meta-analysis
Ankle pump exercises plus anticoagulants reduce postoperative DVT risk Ankle Pump Exercises May Lower DVT Risk After Surgery
This meta-analysis found that adding ankle pump exercises to anticoagulant therapy significantly reduced the risk of postoperative deep vein…
Adding ankle pump exercises to standard blood thinner therapy may significantly lower the risk of dangerous blood clots after surgery.
Endovascular therapy reduces post-thrombotic syndrome severity by 2.0 points compared to standard care
Radiology & Imaging RCT
Endovascular therapy reduces post-thrombotic syndrome severity by 2.0 points compared to standard care Endovascular Therapy Improves Quality of Life for Post-Thrombotic Syndrome
This randomized controlled trial of 225 patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction found that endo…
A new trial shows that endovascular therapy can reduce the severity of post-thrombotic syndrome and improve daily quality of life.
LMWH remains useful when oral anticoagulants are difficult to use safely in venous thromboembolism patients
Drug Pipeline Sys. Review
LMWH remains useful when oral anticoagulants are difficult to use safely in venous thromboembolism patients Low-molecular-weight heparin remains useful when oral anticoagulants are difficult to use safely
This narrative review examines low-molecular-weight heparin dosing, anti-factor Xa monitoring, treatment interruption, and switching strateg…
A review suggests low-molecular-weight heparin stays useful when oral anticoagulants are difficult to use safely for patients with venous th…
Systematic review and meta-analysis of machine learning models for deep vein thrombosis prediction in hospitalized adults
Rheumatology Meta-analysis
Systematic review and meta-analysis of machine learning models for deep vein thrombosis prediction in hospitalized adults Machine learning models predict blood clots in hospitalized adults with high accuracy
This systematic review and meta-analysis synthesized evidence on machine learning-based prediction models for deep vein thrombosis in hospit…
A new analysis of 17 studies shows machine learning models can predict deep vein thrombosis in hospitalized patients with an accuracy score …
Pre-infection vaccination linked to lower cardiovascular and cerebrovascular event risks in SARS-CoV-2 infected individuals
Infectious Disease Sys. Review
Pre-infection vaccination linked to lower cardiovascular and cerebrovascular event risks in SARS-CoV-2 infected individuals Vaccination Before Infection Cuts Heart and Stroke Risks in COVID Patients
This systematic review and meta-analysis examined the association between pre-infection COVID-19 vaccination and cardiovascular outcomes in …
Pre-infection COVID-19 vaccination significantly lowers risks of heart attacks, strokes, and other cardiovascular events in infected individ…
Meta-analysis finds modest PTS reduction with compression stockings after DVT
Rheumatology Meta-analysis
Meta-analysis finds modest PTS reduction with compression stockings after DVT Long-term stockings lower risk of post-thrombotic syndrome in deep vein thrombosis patients
This meta-analysis of 1,775 patients with deep vein thrombosis evaluated long-term graduated compression stockings. It found a modest reduct…
A large review found long-term compression stockings modestly reduce the risk of post-thrombotic syndrome in people with deep vein thrombosi…
Postoperative VTE prediction models show substantial heterogeneity and high bias risk in lung cancer surgery patients undergoing systematic review analysis
Oncology Meta-analysis
Postoperative VTE prediction models show substantial heterogeneity and high bias risk in lung cancer surgery patients undergoing systematic review analysis Existing lung cancer VTE prediction models show mixed results in surgery patients
A systematic review of twenty prediction models for venous thromboembolism in lung cancer surgery patients revealed substantial heterogeneit…
A review of twenty studies found that current tools for predicting blood clots in lung cancer surgery patients vary widely in accuracy and c…
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk
Cardiology Meta-analysis
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk Dabigatran may be safest for brain bleeding risk
This network meta-analysis of 127,267 patients with venous thromboembolism or atrial fibrillation found that all DOACs had lower risk of int…
All blood thinners beat warfarin for brain bleed risk, but dabigatran may be the safest choice.